Intrinsic Value

The intrinsic value of Oxford Nanopore Technologies PLC (ONT) under the Base Case is 135.5 GBX per share. Compared with the current market price of 197.3 GBX, the stock appears Overvalued by 31% .

The intrinsic value is calculated using valuation multiples.

Do our valuations actually work? See backtest results .

ONT Intrinsic Value
135.5 GBX
Overvaluation 31%
Intrinsic Value
Price 197.3 GBX
Alert me when ONT is below its intrinsic value
Today 108.40 · 45.1% below the current price

ONT is valued in line with its history. A premium of this size has been typical over the past 5 years.

Alternatives to ONT

Fundamental Analysis

What Oxford Nanopore Technologies Does

Life Sciences Tools & Services Health Care

Oxford Nanopore Technologies makes DNA and RNA sequencing systems that let customers read genetic material by passing it through tiny nanopores. Its products include handheld and lab-based sequencers, sample prep kits, flow cells, and analysis software. The company sells these tools to research labs, hospitals, universities, biotech firms, and government agencies that need fast genetic data.

Headquarters
United Kingdom UK
Employees
1 335
IPO date
Sep 30, 2021
Read the full company overview
View Company Overview

Oxford Nanopore Technologies has no economic moat

No Moat Narrow Wide

Oxford Nanopore Technologies PLC lacks an economic moat, leaving it vulnerable to competitive pressures and market challenges.

Read the full moat analysis
Financials
Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Recent Events

Past 12 months

Continue ONT Research

Decided on Oxford Nanopore Technologies? Get an email when ONT reaches the price you’d buy at. Free with an account.

Other Oxford Nanopore Technologies listings

What is the Intrinsic Value of one ONT stock?

The intrinsic value for Oxford Nanopore Technologies PLC (ONT) under the Base Case is 135.5 GBX.

Is ONT stock undervalued or overvalued?

Compared with the current market price of 197.3 GBX, the stock appears Overvalued by 31% .

How reliable are our estimates? See how past valuations played out
Back to Top